Euronext Growth Paris
(Ticker symbol: ALCOX)

Nicox Corporate Presentation

An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health

October 30, 2026

Forward-Looking Statements

This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein.

The information contained in this document may be modified without former notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox SA and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox SA and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

None of Nicox SA nor any of its affiliates, directors, officers, employees, advisers or agents, shall have any liability whatsoever (in negligence or otherwise) for the use of these materials by any person or for any loss arising from any use of this document or its contents or otherwise arising in connection with this document. It is not the purpose of this document to provide, and you may not rely on this document as providing, a complete or comprehensive analysis of the Company's financial or commercial position or prospects.

This document is not intended for potential investors and does not constitute or form part of, and should not be construed as, an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained herein shall form the basis of or be relied on in connection with any contract or commitment whatsoever.

Risk factors which are likely to have a material effect on Nicox SA's business are presented in section 3 of the "*Rapport Annuel 2025*" and in section 4 of the "*Rapport Semestriel* 2026" which are available on Nicox SA' website (www.nicox.com).

This presentation may contain links or references to websites operated by other parties. The linked sites are not under the control of Nicox SA, and Nicox SA is not responsible for the data protection strategies or the content available on any other Internet sites linked from our website. Such links do not imply Nicox SA' endorsement of material on any other site, and Nicox SA disclaims all liability with regard to your access to such linked websites. Nicox SA provides links to Internet sites as a convenience to users, and access to any Internet sites linked to or mentioned in this presentation is at your own risk.

Nicox at a glance

Revenue-generating ophthalmology biotech developing sight-saving therapies

Late-stage program in glaucoma with NDAs[1] accepted for review in U.S. and China



Commercial-stage assets and R&D collaborations already in place



Global reach with top-tier worldwide licensees



Significant market opportunity: 80 mn glaucoma patients worldwide[2]



1. New Drug Application
2. World Glaucoma Association website: World Glaucoma Association » What is glaucoma?

NCX 470 U.S. Partner, Kowa, Preparing for Commercial Launch[1,2]

Subject to NDA approval, U.S. launch planned for H2 2027

"*The FDA's acceptance of the NDA for K-911 marks an important milestone as we work toward bringing a potential new treatment option to people living with open-angle glaucoma or ocular hypertension*," said **Joe Barna, CPA, Chief Executive Officer and President of Kowa Pharmaceuticals America, Inc**. "*We're proud to bring Kowa's decades of global ophthalmology experience to the U.S. eye care community, and we look forward to working with the FDA throughout the review process.*"

Following confirmation of a PDUFA target action date of April 30, 2027, Kowa anticipates a U.S. commercial launch in the second half of 2027, subject to approval.

1. Kowa Pharmaceuticals America Announces FDA Acceptance of New Drug Application for K-911, an Investigational IOP-Lowering Eye Drop for Patients with Open-Angle Glaucoma or Ocular Hypertension | Kowa Pharmaceuticals America, Inc.
2. NCX 470 is known as K-911 by Kowa

Corporate highlights

A Proven Track Record

Two commercialized products in the U.S., one in China

Deals in the U.S., Japan, China, and globally with Tier 1 companies

Strategic Transaction Capability

Corporate team with significant transaction and financing experience

Exploring future growth opportunities

NCX 470 : Two NDAs submitted in major markets

NDAs submitted in U.S. (PDUFA date 30 April 2027) and China (accepted for review on 10 September 2026)

Global partnerships with Kowa and Ocumension Therapeutics


Large Potential Market for NCX 470

~$7 bn worldwide glaucoma market

Successful track record of VYZULTA® under partnership with Bausch + Lomb

Nicox Portfolio: Track Record of Ophthalmology Innovation

Near Term Value through NCX 470, a Derisked Product Candidate with Global Potential




1. Revenue sold to Soleus Capital in October 2024

NICOX visible science

NCX 470 Milestones

Significant NCX 470 future news



NDA submission in the U.S. – Achieved June 2026

NDA submission in China – Achieved August 2026

Japan clinical trials results – Trials ongoing

NDA approval in the U.S. – PDUFA[1] date 30 April 2027

Launch in the U.S. – H2 2027, subject to NDA approval

NDA approval in China – Dossier accepted for review on 10 September 2026 by the CDE in China[2]

NDA submission in Japan – Pending clinical data from ongoing trials

Achieved Planned Expected

1. A PDUFA date is the target date by which the U.S. FDA aims to complete its review and issue a decision on an NDA under the Prescription Drug User Fee Act (PDUFA)
2. Center of Drug Evaluation of the National Medical Products Administration in China

NCX 470 highlights and market




- **Novel, fast and dual acting molecule** demonstrating best-in-class IOP lowering efficacy of up to 10mmHg from baseline
- **U.S. and Chinese NDAs filed** based on positive pivotal Phase 3 topline results from the Mont Blanc[1] and Denali[2]
- Preclinical data suggests potential benefits in **retinal protection[3]**
- Large and established glaucoma drug market[4]: **~$7 billion** worldwide, potential to reach $11 to $13 billion after 2030, over **80 million patients**

1. Nicox Press Release October 31, 2022
2. Nicox Press Release August 21, 2025
3. S Gambellone et al. 2023 NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina Translational Vision Science & Technology September 2023, Vol.12, 22
4. Antiglaucoma Drug Market Size, Trends, Growth Report 2034; Glaucoma Therapeutics Market Report by Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Combination Drugs, and Others), Indication (Open Angle Glaucoma, Angle Closure Glaucoma, and Others); Glaucoma Therapeutics Market Size, Growth, Analysis - 2023

Glaucoma: a Significant Worldwide Ophthalmic Disease

Elevated IOP[1] Contributes to Irreversible Optic Nerve Damage, Leading to Progressive Vision Loss




As published in the landmark EMGT study "…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of vision loss progression]"[2]


1. Intraocular Pressure
2. Heijl et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120: 1268-1279

NCX 470 Lowers IOP via a Validated[1] Dual Mechanism Pathway

Clinically Validated in Two Phase 3 trials, and Dual Mechanism of Action Proven in a Phase 3b


Two Pathways for Aqueous Humor Outflow[1,2]





1 Primary or conventional outflow normally accounts for ~60% to 80% of outflow

2 Secondary or uveoscleral outflow normally accounts for ~20% to 40% of outflow



Stimulated by nitric oxide (NO)

Stimulated by prostaglandins (PGAs)

1. Whistler Phase 3b trial
2. Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial presented at AGS 2026 Authors: Arthur J. Sit, SM, MD Professor, Arash Kazemi, MD, and Siobhan Garbutt, PhD

Unmet Medical Needs for Glaucoma Treatment

Despite having well established first-line therapies, including the standard-of-care, latanoprost, patients do not react to glaucoma medications in the same way, and therefore ophthalmologists need multiple treatment options

40% of patients do not achieve their target IOP on existing monotherapies[1] requiring ophthalmologists to adjust or change the medication

Many patients require >1 medication which leads to compliance issues[2,3]

Tolerability issues with some medications lead to discontinuations, patient management issues, and/or compliance issues[4]

1. Kass et al, Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol, 2010; 128:276-287
2. Robin AL et al, Does adjunctive glaucoma treatment therapy affect adherence to the initial primary therapy? Ophthalmology. 2005; 112:863-868
3. Robin et al, Adherence in glaucoma: Objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533-540
4. Beckers HJM et al. Side effects of commonly used glaucoma medications: comparison of tolerability, chance of discontinuation, and patient satisfaction. *Graefe's Archive for Clinical and Experimental Ophthalmology* 2008;246(10):1485-90

NCX 470 NDA submitted in U.S and in China



- U.S. NDA submitted in June 2026 with a PDUFA date of 30 April 2027
- China NDA submitted in August 2026 and dossier accepted for review by the CDE[2] on 10 September 2026
- Composition of matter patent to 2029, with potential for extension to 2034 in the United States, and formulation patent to 2039
- Additional marketing exclusivity may be available based on the status as a New Chemical Entity

1. Subject to U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)
2. Center for Drug Evaluation of the National Medical Products Administration in China

NCX 470 Clinical Program

Primary objective of non-inferiority met, supporting NDA submission

Mont Blanc[1]

N = 691

56 clinical sites in the U.S. & one site in China

Adaptive design selected the 0.1% concentration

Denali[2]

N = 696

65 clinical sites in the U.S. & 25 in China

Included a safety extension period from 6 months through to 12 months

Jointly conducted and equally financed with Chinese partner Ocumension Therapeutics



Image for illustrative purposes only

Phase 3 studies were designed to demonstrate safety and efficacy of NCX 470 0.1% vs. latanoprost 0.005%.

The reduction of IOP from time-matched baseline was evaluated at pre-established time points.

Supportive data was also generated in the Phase 2 Dolomites trial and the Phase 3b Whistler trial.

1. MONT BLANC: Nicox Press release October 31, 2022
2. DENALI: Nicox Press Release August 21, 2025


NCX 470 Phase 3 Trial Design[1] – Efficacy Assessment Period

NCX 470 vs. standard of care, Latanoprost

Randomized, controlled, double-masked, parallel design trial. Patients with open angle glaucoma or ocular hypertension were randomized 1:1 to once-daily treatment with NCX 470 0.1% or latanoprost 0.005%

Primary Endpoint: Mean IOP reduction from time-matched baseline at 8 AM and 4 PM at the week 2, week 6 and month 3 visits

Enrollment: The trials enrolled 691 patients (Mont Blanc: up to 3 months on treatment) and 696 patients (Denali: up to 12 months on treatment) across all arms (including ~30 patients on NCX 470 0.065% in the adaptive design part of Mont Blanc). Both trials included sites in U.S. and China




1. This schematic reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the Mont Blanc trial
2. Wash-out period according to the patient's previous IOP-lowering treatment
3. Measurement of the primary endpoint. All Denali subjects continued to 6 months, and a portion to 12 months, in the safety extension

Rapid and Sustained IOP-Lowering Effects


Demonstrated in two Phase 3 studies

Mont Blanc[1]



- NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333
- IOP-Lowering from Baseline was 8.0 to 9.7 mmHg for NCX 470 vs. 7.1 to 9.4 mmHg for latanoprost
- 4 out of 6 timepoints significantly lower than latanoprost

Denali[2]



- NCX 470 0.1%: N = 348 Latanoprost 0.005%: N = 348
- IOP-Lowering from Baseline was 7.9 to 10.0 mmHg for NCX 470 vs. 7.1 to 9.8 mmHg for latanoprost
- 3 out of 6 timepoints significantly lower than latanoprost

* Denotes statistically significant differences vs latanoprost ($p<0.049$ for Mont Blanc, $p<0.05$ for Denali)

1. Fechtner et al., AJO, 2024 Aug;264:66-74
2. Nicox Press Release August 21, 2025

NCX 470 Phase 3 Results Confirm Robust Efficacy[1,2,3]

Based on Topline Results from both Pivotal Trials[4]

- IOP-lowering effect from baseline was **7.9 - 10.0 mmHg for NCX 470** vs. 7.1 to 9.8 mmHg for latanoprost in the trials.
- **Statistical non-inferiority was met vs. latanoprost** in the primary efficacy analysis of both trials. These trials therefore met the efficacy requirements for approval in the U.S. and China.
- **NCX 470 reduced IOP significantly** at 4/6 timepoints in Mont Blanc ($p<0.049$) and 3/6 in Denali ($p<0.05$), though the secondary endpoint of overall superiority to latanoprost was not achieved.
- IOP reduction for NCX 470 vs. latanoprost was **numerically greater at 6 out of 6 timepoints** in Mont Blanc and **5 out of 6 timepoints** in Denali.

1. Data from Mont Blanc reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial.
2. Fechtner et al, American Journal of Ophthalmology, 2024, 264:66-74
3. Nicox Press Release, August 21, 2025
4. All comparisons are based on NCX 470 0.1% and Latanoprost 0.005%

NCX 470 Well Tolerated in Both Phase 3 Trials[1,2,3]

No ocular or non ocular serious adverse events related to NCX 470

	Mont Blanc		Denali	
	NCX 470	Latanoprost	NCX 470	Latanoprost
Hyperemia (most common adverse effect)	Ocular Hyperemia 11.9%	3.3%	Conjunctival Hyperemia 22.0%	9.2%
Low discontinuation rate	4.3%	5.1%	10.1%	6.6%
Rate of discontinuation due to adverse event	2.4%	1.8%	0.9%	0.3%

1. Data from Mont Blanc reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial.
2. Fechtner et al, American Journal of Ophthalmology, 2024, 264:66-74
3. Nicox Press Release, 21 August 2025


NCX 470 Post hoc Data Further Differentiates vs. Standard of Care

All Comparisons Are Based on NCX 470 0.1% and Latanoprost 0.005% in Mont Blanc[1,2]

- Statistically significantly greater percentage of patients achieve **≤ 18mmHg** IOP on NCX 470 compared to latanoprost
- Mean **percentage reduction in IOP greater on NCX 470** than on latanoprost
- **In eyes with an initial IOP of ≤ 28 mmHg the IOP-lowering effect from baseline was statistically significantly greater for NCX 470 compared to latanoprost** at the majority of timepoints measured
- **NCX 470 demonstrates a consistent lowering of IOP regardless of the baseline IOP**, whereas the reduction in IOP with latanoprost is dependent on the baseline IOP
- **A statistically significantly greater proportion of patients who received NCX 470 showed an IOP reduction of greater than 10 mmHg from baseline,** compared to those on latanoprost

1. This data reflects the dosage arms which continued in the trial and do not include the NCX 470 0.065% dose which was only in the adaptive design portion of the trial.
2. The full data from the Mont Blanc Phase 3 trial is available on the Nicox website at www.nicox.com

NCX 470 – Publications and Presentations



A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study

ROBERT FECHTNER, STEVEN MANSBERGER, JAMES BRANCH, JAY MULANEY, SARA ZIEBELL, KRISI LOPEZ, AND DOUG HUBATSCH


Authors' Conclusion: The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, **NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.**

AMERICAN GLAUCOMA SOCIETY


2026 AGS FEB 19-22 OMNI RANCHO LAS PALMAS RESORT RANCHO MIRAGE, CA



A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial
Authors: S. Asrani, MD, Professor of Ophthalmology, and D. Hubatsch, MS




Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial
Authors: Arthur J. Sit, SM, MD Professor, Arash Kazemi, MD, and Siobhan Garbutt, PhD



Outcomes in the United States Subgroup of the Denali Trial: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension
Authors: Jason Bacharach, MD and Doug Hubatsch, MS

Posters are available in the "Publications" section of our website: https://www.nicox.com/pipeline-markets-and-science/#publications

Global Licensing of NCX 470



Kowa – NCX 470 Partnership

Two value-creating deals

- Founded in Japan in 1894; Active worldwide in multiple domains including life sciences[1]
- ~8000 employees with an annual group revenue of $4.9 billion
- Kowa's pharmaceutical business is global and expanding through its network of affiliates in the United States, Europe and Asia.
- Team of medical representatives in Japan and a franchise in glaucoma
- Strong commercial pharmaceutical presence in the U.S.
- NDA PDUFA date 30 April 2027 with U.S. launch expected in H2 2027

February 2024	July 2025
Japan	**United States** and all territories outside China, Korea, Southeast Asia and Japan
€3 million upfront, up to €30.5 million total (€6 million received)	**€7.5 million upfront, up to €127 million total (€15.5 million received)**
Royalties 7% to 12%	**Royalties Tiered up to 20%**

1. Kowa Company, Ltd. and Kowa Pharmaceuticals America, Inc.

Ocumension – NCX 470 Partnership

Shareholder of Nicox and Commercial partner for ZERVIATE China

- Chinese company created in 2018 and dedicated to ophthalmology[1]
- Listed on the Hong Kong stock exchange since 2020 - ~$800 million market cap
- Portfolio of 43 products with 27 commercialized, $116 million revenue in 2025 (+93%)
- Approximately 550 employees, including over 330 in commercial
- Local manufacturing and commercial capabilities in China
- NDA submitted in China in August 2026 and accepted for review on 10 September 2026

December 2018

China,
Korea,
Southeast Asia

Total of €18 million paid to Nicox in milestones (non-dilutive financing) plus cost contributions to Denali (50%) and Mont Blanc (one Chinese site)

Royalties
6% to 12% of future net sales

1. Ocumension website

Commercial Products and Partnerships

VYZULTA™
(latanoprostene bunod ophthalmic solution), 0.024%

BAUSCH + LOMB

Same mechanism of action as NCX 470

Launched in over 15 countries including the U.S.[4]

ZERVIATE
cetirizine ophthalmic solution, 0.24%

OcuMension 欧康维视

5% to 9% royalties on annual net sales in China[1]

First Commercial sale in China in Q4 2024

HARROW
Your patients. Our purpose.

8% to 15% royalties on annual net sales in the U.S.[2]

Launched[3] in the U.S. in 2020

1. Ocumension has rights in Chinese and Southeast Asian markets
2. ZERVIATE is commercialized in the U.S. by Harrow, who also have rights for Canada.
3. Initially launched by Eyevance, who was acquired by Santen. Harrow acquired the ZERVIATE rights from Santen in 2023.
4. Revenue sold to Soleus Capital in October 2024

Financial information

Nicox is listed on Euronext Growth Paris (Ticker symbol: ALCOX)

Cash runway[1]

12+ months

Analyst coverage

Yi Chen
HC Wainwright

Financial Information (links):

↗ Annual Report 2025
↗ Half-yearly Report 2026
↗ Stock Information

1. As at the date of this presentation

Corporate highlights

A Proven Track Record

Two commercialized products in the U.S., one in China

Deals in the U.S., Japan, China, and globally with Tier 1 companies

Strategic Transaction Capability

Corporate team with significant transaction and financing experience

Exploring future growth opportunities

NCX 470 : Two NDAs submitted in major markets

NDAs submitted in U.S. (PDUFA date 30 April 2027) and China (accepted for review on 10 September 2026)

Global partnerships with Kowa and Ocumension Therapeutics

Large Potential Market for NCX 470

~$7 bn worldwide glaucoma market

Successful track record of VYZULTA® under partnership with Bausch + Lomb

Euronext Growth Paris
(Ticker symbol: ALCOX)

Nicox S.A.
Sundesk Sophia Antipolis
Emerald Square Bâtiment C
rue Evariste Galois
06410 Biot, France
T: +33 (0)4 97 24 53 00

communications@nicox.com
www.nicox.com